EGFR and pancreatic neoplasm: A trial of the PSMA XPAT molecule (JANX007) produced PSA50 responses in 5/6 patients dosed at 0.2 mg or above, but no partial response with doses up to 3 mg (NCT05519449); the EGFR XPAT molecule (JANX008) produced 1 partial response (PR) in an NSCLC patient at a 0.15 mg dose, but no additional response in 10 other patients dosed as high as 1.25 mg (NCT05783622); the EGFR Probody (CX-904) generated 2/6 PRs in pancreatic cancer patients, but no objective response in 20 other patients in the trial, across multiple indications and at similar or higher doses (NCT05387265).